Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review
about
Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor MicroenvironmentElevated Gab2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levelsKaposi's Sarcoma-Associated Herpesvirus Hijacks RNA Polymerase II To Create a Viral Transcriptional Factory.Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review.Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphomaNovel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature.Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort.Integrated precision medicine: the role of electronic health records in delivering personalized treatment.New targeted therapies for malignant lymphoma based on molecular heterogeneity.Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy.A Review of Autologous Stem Cell Transplantation in Lymphoma.MicroRNA-187 induces diffuse large B-cell lymphoma cell apoptosis via targeting BCL6.Identification of distinct subgroups of EBV-positive post-transplant diffuse large B-cell lymphoma.PIK3CA amplification and PTEN loss in diffused large B-cell lymphoma.Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.Current Progress in EBV-Associated B-Cell Lymphomas.Low-dose radiotherapy in diffuse large B-cell lymphoma.Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma.Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study.B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive.Retrospective screening of microarray data to identify candidate IFN-inducible genes in a HTLV-1 transformed model.FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy.Effect of mechanistic target of rapamycin inhibitors on postrenal transplantation malignancy: A nationwide cohort study
P2860
Q28073613-17EB4D02-EFAD-415E-8229-720D2AD23069Q33576659-87D169D4-5C37-4A06-825A-9C4A92925C6EQ33690895-2E6CB8A4-6E88-4277-9CAC-DA349ECB519BQ36302961-1E98058D-B07D-41C4-A82F-3B2C684848FFQ37240290-80F4E5C2-C546-46A6-85C4-E6B0D996D038Q37363925-7CEC246F-0616-45F6-B28A-0596BBF972EBQ37647935-A3981B57-3097-4425-9577-B138F400FD59Q38756680-8A588094-7610-4FCC-A17E-82D4AFF21684Q38787141-96887A8E-E768-4827-9303-1FA3DA8BEA94Q38989496-C5EC5414-66D8-4223-8FC9-17E823BA8E48Q39147488-4FBB005F-D05C-4DC8-9C2C-9038A073BB15Q39288544-25C33B70-FEAB-4414-BC5E-D3B35175A060Q39647418-DE98322E-9AEE-46F4-AF8C-7E3C6B8443A0Q40383136-6C88D034-8523-499C-AA96-FDB4F729C2B7Q42371625-37C2064D-71F1-449D-9AE6-63884C84BBD3Q42378327-B52D6BD5-C5BE-4CB3-A647-73302FB811E2Q43525091-D6B1E6B6-10F3-4028-ABB8-704F152DBBCBQ47606345-9766EF3F-2746-4ECC-A72F-7565A4D28157Q47634173-CC70357B-7BBD-4D85-9D52-C93E02F46E76Q47737291-B2E31492-12A5-466E-8764-FAFCC87BD866Q48129205-6A263CAC-79A8-4F3A-919C-C648BF8521EAQ48792987-830147F2-E91A-4C46-A2AC-F18E04845E5AQ50056654-E5296EFD-25B0-4E95-98DE-3953176E5F67Q52668325-C620E909-14CE-470B-85C5-8E74843C360EQ52721823-B247EDA4-4393-40EF-AE51-30920A6B0B48Q53688633-93939BC4-1B7B-485D-B31A-947C3EF6A670Q58772577-26B05AC1-2D81-42CD-A743-27475EAE6677
P2860
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Novel drug targets for persona ...... mphoma: a comprehensive review
@ast
Novel drug targets for persona ...... mphoma: a comprehensive review
@en
Novel drug targets for persona ...... mphoma: a comprehensive review
@nl
type
label
Novel drug targets for persona ...... mphoma: a comprehensive review
@ast
Novel drug targets for persona ...... mphoma: a comprehensive review
@en
Novel drug targets for persona ...... mphoma: a comprehensive review
@nl
prefLabel
Novel drug targets for persona ...... mphoma: a comprehensive review
@ast
Novel drug targets for persona ...... mphoma: a comprehensive review
@en
Novel drug targets for persona ...... mphoma: a comprehensive review
@nl
P2860
P921
P3181
P1433
P1476
Novel drug targets for persona ...... mphoma: a comprehensive review
@en
P2093
Paul O Hassa
Rosalba Camicia
P2860
P2888
P3181
P356
10.1186/S12943-015-0474-2
P407
P5008
P577
2015-12-11T00:00:00Z
P5875
P6179
1007141934